The Rosen Law Firm  announced today that a class action has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Barrier Therapeutics, Inc. common stock during the period between April 29, 2004 and June 29, 2005.

Shareholders who purchased Barrier stock in the Initial Public Offering on April 29, 2004 and/or in its Secondary Offering on February 9, 2005 are also included in this class action.

To join the Barrier securities litigation please click on the link at the upper right side of this page.

The complaint charges Barrier and certain of its officers and directors with violations of the Securities Act of 1933 and Securities Exchange Act of 1934. Barrier is a biopharmaceutical company, engaged in the discovery, development, and commercialization of pharmaceutical products in the field of dermatology. The complaint alleges that Barrier made a series of materially false and misleading statements concerning the Company\'s business and products under development. In particular, the Complaint alleges that these statements were materially false and misleading because they failed to disclose and misrepresented the following adverse facts: (i) that the Company had failed to perform its clinical trials in conformity with FDA guidelines as they had failed to disclose that they had secretly substituted the petroleum base within Zimycan, the effect of which was to substantially lessen the likelihood that the drug could achieve FDA approval; (ii) that Hyphanox did not have a better safety or efficacy profile than fluconazole/Diflucan and, in fact, as investors ultimately learned, Hyphanox was significantly less effective than fluconazole/Diflucan; and (iii) as a result of the foregoing, defendants lacked any reasonable basis for their positive statements about Barrier.